Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor

ConclusionThese results suggested that no dose adjustment might be necessary when administering dotinurad to patients with mild-to-moderate renal dysfunction.ClinicalTrials.gov Identifier: NCT02347046.
Source: Clinical and Experimental Nephrology - Category: Urology & Nephrology Source Type: research